KLRK1 antibody

Synonyms:KLRK1 antibody, CD314 antibody, D12S2489E antibody, KLR antibody, NKG2-D antibody, NKG2D antibody
Catalogue No.:FNab10477Reactivity:Human, Mouse
Host:RabbitTested Application:ELISA, WB
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
Product Name
KLRK1 antibody
Catalogue No.
FNab10477
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
NKG2-D type II integral membrane protein
Alternative Names
KLRK1 antibody, CD314 antibody, D12S2489E antibody, KLR antibody, NKG2-D antibody, NKG2D antibody
UniProt ID
P26718
Observed MW
30 kDa
Application
Tested Applications
ELISA, WB
Recommended dilution
WB: 1:500-1:2000
Validated Images
HepG2 cells were subjected to SDS PAGE followed by western blot with FNab10477(KLRK1 Antibody) at dilution of 1:1000
Background
Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins, where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster.